Skip to content

Platelet-rich plasma injection for chronic rotator cuff tendinopathy

Platelet-rich plasma injection for chronic rotator cuff tendinopathy:a randomized controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-16010223
Enrollment
Unknown
Registered
2016-12-22
Start date
2017-02-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rotator cuff tendinopathy

Interventions

PRP group:subacromial injection of 5 ml platelet-rich plasm per week, total two injections
Control group :subacromial injection of 5 ml saline per week, total two injections

Sponsors

Hong-hui Hospital, Xi'an Jiaotong University College of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with shoulder impingement syndrome or a partial-thickness rotator cuff tear; 2. Diagnosis based on MRI; 3. Male or female, aged 35 to 75 years old.

Exclusion criteria

Exclusion criteria: 1. Full thickness rotator cuff tears; 2. Participants with a history of significant trauma.(fracture, dislocation, instability and so on), surgery, osteoarthritis or other significant pathology of the affected shoulder not related to the rotator cuff; 3. Patient is unable to consent; 4. History of injection treatment of shoulders; 5. Contraindications to PRP (listed below). PRP contraindications: 1. History of diabetes mellitus; 2. Platelet abnormality or platelet count <100×10^9/l; 3. Hematological disorder; 4. Serum hemoglobin <11 g/dl; 5. Use of systemic cortisone; 6. Use of any anticoagulant; 7. Evidence of gangrene, ulcers or peripheral vascular disease; 8. History of hepatic or renal impairment or dialysis; 9. Patient is known to have a psychological, developmental, physical, emotional or social disorder that may interfere with compliance with study requirements; 10. History of alcohol or drug abuse; 11. Patient has a religious or cultural conflict with the use of platelet gel or blood products; 12. Patient has inadequate venous access for blood draw; 13. Patient is currently receiving or has received radiation or chemotherapy within the last 3 months prior to the study; 14. Female participants who are pregnant, lactating or planning pregnancy during the course of the study.

Design outcomes

Primary

MeasureTime frame
Shoulder pain and disablity index;

Secondary

MeasureTime frame
Constant-Mulary score for shoulder function;Oxford shoulder score;visual analogue scale for pain;range of motion;subjective satisfaction of patients;

Countries

China

Contacts

Public ContactHui Kang

Hong-hui Hospital, Xi'an Jiaotong University College of Medicine

dockanghui@126.com+86 13992889166

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026